سعر نينلارو 3 مجم 3 كبسولات 2026

Ninlaro (ixazomib) 3 mg capsules, pack of 3 (Takeda).

• In combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.Population: Adults with relapsed multiple myelomaDailyMed / FDA

• Most common (≥20%): diarrhea, constipation, thrombocytopenia, peripheral neuropathy, nausea, peripheral edema, vomiting, back pain.International label, same product · DailyMed / FDA

• None listed as absolute contraindications beyond hypersensitivity considerations in the US label highlights; follow full label — do not use if hypersensitivity to ixazomib.International label, same product · DailyMed / FDA

• Thrombocytopenia; gastrointestinal toxicities (diarrhea, constipation, nausea, vomiting); peripheral neuropathy; peripheral edema; cutaneous reactions; hepatotoxicity; embryo-fetal toxicity — advise effective contraception.International label, same product · DailyMed / FDA

• Can cause fetal harm; advise females of reproductive potential and males with female partners to use effective contraception during treatment and for 90 days after the last dose (per US label).International label, same product · DailyMed / FDA
• Advise women not to breastfeed during treatment with Ninlaro and for 90 days after the final dose.International label, same product · DailyMed / FDA

• Ixazomib: Inhibits the beta5 subunit of the 20S proteasome, inducing apoptosis in multiple myeloma cells.